Applied DNA Signs Master Services Agreement with Schreiner Group to Deliver SigNature DNA Labels to Protect Pharmaceutical Supply Chains - Seite 2

About Schreiner Group

Schreiner Group GmbH & Co. KG is an internationally active German family-owned business operating in the printing and film-converting industry. The company offers tailored products, solutions and services for the pharmaceutical and medical device industry, logistics, mechanical engineering, the electronics and automotive industries. In addition, Schreiner Group’s customer base includes banks and government agencies. The product portfolio encompasses innovative specialty labels, including self-adhesive functional components, RFID labels, printed electronics, and security solutions for product, brand and document protection. Schreiner Group employs more than 1,100 people around the globe, generating annual sales of more than 180 million euros, and is headquartered in Oberschleissheim near Munich (Germany). Schreiner Group’s high-tech labels are also produced in Blauvelt (New York, USA) and in Fengpu (Shanghai, China). The company’s facilities extend across a total area of 72,000 square meters.

For more information, visit schreiner-group.com.

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.